Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function

Roberto Castelli, Giorgio Lambertenghi Deliliers, Riccardo Colombo, Guido Moreo, Paolo Gallipoli, Giuseppe Pantaleo

Research output: Contribution to journalArticle

Abstract

The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by bone marrow failure and a risk of progression to acute myeloid leukemia (AML). Anemia affects the course of disease, quality of life (QOL), and cognitive function of MDS patients. Erythroid-stimulating agents (ESAs) are effective; however, not all patients respond to ESAs. To evaluate the effectiveness of a biosimilar epoetin α (Binocrit) for the treatment of anemia in low-/intermediate-1 risk MDS patients and to evaluate the impact of ESAs on QOL and on cognitive function, 24 consecutive patients aged over 65 years were treated with Binocrit at 40,000 IU once a week for 12 weeks and were followed for at least 3 months. Responsive patients continued with 40,000 IU once a week for a further 12 weeks. Changes in QOL were assessed by the Functional Assessment of Cancer Therapy-Anemia (FACT-An), while cognitive assessment was carried out by mini-mental state examination (MMSE). All patients completed 12 weeks of therapy. Sixteen patients (66.67 %) achieved an erythroid response (ER), 15 patients (62.5 %) became transfusion independent and remained free from transfusion requirement for at least 3 months, while two patients had reduction in transfusion requirement of at least four RBC transfusions/8 weeks compared with the pretreatment transfusion requirement. Seven patients were nonresponders (29.1 %), of whom four patients were low risk and three intermediate-I risk. Seven transfusion-independent patients were low risk, and eight were intermediate-1 risk. Median hemoglobin (Hb) values were significantly higher after treatment in responders (p

Original languageEnglish
Pages (from-to)1523-1529
Number of pages7
JournalAnnals of Hematology
Volume93
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

Biosimilar Pharmaceuticals
Myelodysplastic Syndromes
Anemia
Quality of Life
Brain
Epoetin Alfa
Cognition

Keywords

  • Anemia
  • Biosimilar epoetin α (Binocrit)
  • Cognitive function
  • Erythroid-stimulating agents (ESAs)
  • Myelodysplastic syndromes (MDS)
  • Quality of life (QOL)

ASJC Scopus subject areas

  • Hematology

Cite this

Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. / Castelli, Roberto; Deliliers, Giorgio Lambertenghi; Colombo, Riccardo; Moreo, Guido; Gallipoli, Paolo; Pantaleo, Giuseppe.

In: Annals of Hematology, Vol. 93, No. 9, 2014, p. 1523-1529.

Research output: Contribution to journalArticle

Castelli, Roberto ; Deliliers, Giorgio Lambertenghi ; Colombo, Riccardo ; Moreo, Guido ; Gallipoli, Paolo ; Pantaleo, Giuseppe. / Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. In: Annals of Hematology. 2014 ; Vol. 93, No. 9. pp. 1523-1529.
@article{e7ff43bec3034050a2610ad99b2fd528,
title = "Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function",
abstract = "The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by bone marrow failure and a risk of progression to acute myeloid leukemia (AML). Anemia affects the course of disease, quality of life (QOL), and cognitive function of MDS patients. Erythroid-stimulating agents (ESAs) are effective; however, not all patients respond to ESAs. To evaluate the effectiveness of a biosimilar epoetin α (Binocrit) for the treatment of anemia in low-/intermediate-1 risk MDS patients and to evaluate the impact of ESAs on QOL and on cognitive function, 24 consecutive patients aged over 65 years were treated with Binocrit at 40,000 IU once a week for 12 weeks and were followed for at least 3 months. Responsive patients continued with 40,000 IU once a week for a further 12 weeks. Changes in QOL were assessed by the Functional Assessment of Cancer Therapy-Anemia (FACT-An), while cognitive assessment was carried out by mini-mental state examination (MMSE). All patients completed 12 weeks of therapy. Sixteen patients (66.67 {\%}) achieved an erythroid response (ER), 15 patients (62.5 {\%}) became transfusion independent and remained free from transfusion requirement for at least 3 months, while two patients had reduction in transfusion requirement of at least four RBC transfusions/8 weeks compared with the pretreatment transfusion requirement. Seven patients were nonresponders (29.1 {\%}), of whom four patients were low risk and three intermediate-I risk. Seven transfusion-independent patients were low risk, and eight were intermediate-1 risk. Median hemoglobin (Hb) values were significantly higher after treatment in responders (p",
keywords = "Anemia, Biosimilar epoetin α (Binocrit), Cognitive function, Erythroid-stimulating agents (ESAs), Myelodysplastic syndromes (MDS), Quality of life (QOL)",
author = "Roberto Castelli and Deliliers, {Giorgio Lambertenghi} and Riccardo Colombo and Guido Moreo and Paolo Gallipoli and Giuseppe Pantaleo",
year = "2014",
doi = "10.1007/s00277-014-2070-8",
language = "English",
volume = "93",
pages = "1523--1529",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function

AU - Castelli, Roberto

AU - Deliliers, Giorgio Lambertenghi

AU - Colombo, Riccardo

AU - Moreo, Guido

AU - Gallipoli, Paolo

AU - Pantaleo, Giuseppe

PY - 2014

Y1 - 2014

N2 - The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by bone marrow failure and a risk of progression to acute myeloid leukemia (AML). Anemia affects the course of disease, quality of life (QOL), and cognitive function of MDS patients. Erythroid-stimulating agents (ESAs) are effective; however, not all patients respond to ESAs. To evaluate the effectiveness of a biosimilar epoetin α (Binocrit) for the treatment of anemia in low-/intermediate-1 risk MDS patients and to evaluate the impact of ESAs on QOL and on cognitive function, 24 consecutive patients aged over 65 years were treated with Binocrit at 40,000 IU once a week for 12 weeks and were followed for at least 3 months. Responsive patients continued with 40,000 IU once a week for a further 12 weeks. Changes in QOL were assessed by the Functional Assessment of Cancer Therapy-Anemia (FACT-An), while cognitive assessment was carried out by mini-mental state examination (MMSE). All patients completed 12 weeks of therapy. Sixteen patients (66.67 %) achieved an erythroid response (ER), 15 patients (62.5 %) became transfusion independent and remained free from transfusion requirement for at least 3 months, while two patients had reduction in transfusion requirement of at least four RBC transfusions/8 weeks compared with the pretreatment transfusion requirement. Seven patients were nonresponders (29.1 %), of whom four patients were low risk and three intermediate-I risk. Seven transfusion-independent patients were low risk, and eight were intermediate-1 risk. Median hemoglobin (Hb) values were significantly higher after treatment in responders (p

AB - The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by bone marrow failure and a risk of progression to acute myeloid leukemia (AML). Anemia affects the course of disease, quality of life (QOL), and cognitive function of MDS patients. Erythroid-stimulating agents (ESAs) are effective; however, not all patients respond to ESAs. To evaluate the effectiveness of a biosimilar epoetin α (Binocrit) for the treatment of anemia in low-/intermediate-1 risk MDS patients and to evaluate the impact of ESAs on QOL and on cognitive function, 24 consecutive patients aged over 65 years were treated with Binocrit at 40,000 IU once a week for 12 weeks and were followed for at least 3 months. Responsive patients continued with 40,000 IU once a week for a further 12 weeks. Changes in QOL were assessed by the Functional Assessment of Cancer Therapy-Anemia (FACT-An), while cognitive assessment was carried out by mini-mental state examination (MMSE). All patients completed 12 weeks of therapy. Sixteen patients (66.67 %) achieved an erythroid response (ER), 15 patients (62.5 %) became transfusion independent and remained free from transfusion requirement for at least 3 months, while two patients had reduction in transfusion requirement of at least four RBC transfusions/8 weeks compared with the pretreatment transfusion requirement. Seven patients were nonresponders (29.1 %), of whom four patients were low risk and three intermediate-I risk. Seven transfusion-independent patients were low risk, and eight were intermediate-1 risk. Median hemoglobin (Hb) values were significantly higher after treatment in responders (p

KW - Anemia

KW - Biosimilar epoetin α (Binocrit)

KW - Cognitive function

KW - Erythroid-stimulating agents (ESAs)

KW - Myelodysplastic syndromes (MDS)

KW - Quality of life (QOL)

UR - http://www.scopus.com/inward/record.url?scp=84905573287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905573287&partnerID=8YFLogxK

U2 - 10.1007/s00277-014-2070-8

DO - 10.1007/s00277-014-2070-8

M3 - Article

C2 - 24711171

AN - SCOPUS:84905573287

VL - 93

SP - 1523

EP - 1529

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 9

ER -